| Reference |
|---|
Cao Z, Yang X, Yang W, Chen F, Jiang W, Zhan S, et al. Modulation of Dendritic Cell Function via Nanoparticle-Induced Cytosolic Calcium Changes. ACS Nano. 2024;18:7618-7632 pubmed publisher |
Bhatta R, Han J, Liu Y, Bo Y, Lee D, Zhou J, et al. Metabolic tagging of extracellular vesicles and development of enhanced extracellular vesicle based cancer vaccines. Nat Commun. 2023;14:8047 pubmed publisher |
Lin Y, Chen C, Ku Y, Wang L, Hung C, Lin Z, et al. A modified SELEX approach to identify DNA aptamers with binding specificity to the major histocompatibility complex presenting ovalbumin model antigen. RSC Adv. 2023;13:32681-32693 pubmed publisher |
Deng P, Wang Z, Chen J, Liu S, Yao X, Liu S, et al. RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer. J Clin Invest. 2022;132: pubmed publisher |
Wang Z, Xu F, Hu J, Zhang H, Cui L, Lu W, et al. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity. J Immunother Cancer. 2021;9: pubmed publisher |
von Roemeling C, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, et al. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun. 2020;11:1508 pubmed publisher |
Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, et al. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Invest. 2019;129:4850-4862 pubmed publisher |
Duan X, Chan C, Han W, Guo N, Weichselbaum R, Lin W. Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. Nat Commun. 2019;10:1899 pubmed publisher |
Rota G, Ludigs K, Siegert S, Tardivel A, Morgado L, Reith W, et al. T Cell Priming by Activated Nlrc5-Deficient Dendritic Cells Is Unaffected despite Partially Reduced MHC Class I Levels. J Immunol. 2016;196:2939-46 pubmed publisher |
Steele S, Radlinski L, Taft Benz S, Brunton J, Kawula T. Trogocytosis-associated cell to cell spread of intracellular bacterial pathogens. elife. 2016;5: pubmed publisher |
Tähtinen S, Kaikkonen S, Merisalo Soikkeli M, Grönberg Vähä Koskela S, Kanerva A, Parviainen S, et al. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS ONE. 2015;10:e0131242 pubmed publisher |
Sasaki K, Takada K, Ohte Y, Kondo H, Sorimachi H, Tanaka K, et al. Thymoproteasomes produce unique peptide motifs for positive selection of CD8(+) T cells. Nat Commun. 2015;6:7484 pubmed publisher |
Dura B, Dougan S, Barisa M, Hoehl M, Lo C, Ploegh H, et al. Profiling lymphocyte interactions at the single-cell level by microfluidic cell pairing. Nat Commun. 2015;6:5940 pubmed publisher |
Tellam J, Zhong J, Lekieffre L, Bhat P, Martinez M, Croft N, et al. mRNA Structural constraints on EBNA1 synthesis impact on in vivo antigen presentation and early priming of CD8+ T cells. PLoS Pathog. 2014;10:e1004423 pubmed publisher |
Cebrián C, Zucca F, Mauri P, Steinbeck J, Studer L, Scherzer C, et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun. 2014;5:3633 pubmed publisher |
Ramakrishnan R, Tyurin V, Tuyrin V, Veglia F, Condamine T, Amoscato A, et al. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol. 2014;192:2920-31 pubmed publisher |
Sauer B, Schmalstieg W, Howe C. Axons are injured by antigen-specific CD8(+) T cells through a MHC class I- and granzyme B-dependent mechanism. Neurobiol Dis. 2013;59:194-205 pubmed publisher |
Kulpa D, Del Cid N, Peterson K, Collins K. Adaptor protein 1 promotes cross-presentation through the same tyrosine signal in major histocompatibility complex class I as that targeted by HIV-1. J Virol. 2013;87:8085-98 pubmed publisher |
Pham C, Woo M, Kim Y, Park S, Kwon M. An anti-nucleic acid antibody delivers antigen to the cross-presentation pathway in dendritic cells and potentiates therapeutic antitumor effects. J Immunol. 2012;189:5755-63 pubmed publisher |
Iyori M, Zhang T, Pantel H, Gagne B, Sentman C. TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells. J Immunol. 2011;187:3087-95 pubmed publisher |
Hoves S, Sutton V, Haynes N, Hawkins E, Fernández Ruiz D, Baschuk N, et al. A critical role for granzymes in antigen cross-presentation through regulating phagocytosis of killed tumor cells. J Immunol. 2011;187:1166-75 pubmed publisher |
Lim T, Mortellaro A, Lim C, Hämmerling G, Ricciardi Castagnoli P. Mechanical interactions between dendritic cells and T cells correlate with T cell responsiveness. J Immunol. 2011;187:258-65 pubmed publisher |
Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M, et al. Type I IFNs control antigen retention and survival of CD8?(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol. 2011;186:5142-50 pubmed publisher |
Elliott J, Wahle J, Yokoyama W. MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med. 2010;207:2073-9 pubmed publisher |
Xie J, Zhu H, Guo L, Ruan Y, Wang L, Sun L, et al. Lectin-like oxidized low-density lipoprotein receptor-1 delivers heat shock protein 60-fused antigen into the MHC class I presentation pathway. J Immunol. 2010;185:2306-13 pubmed publisher |
Yewdall A, DRUTMAN S, Jinwala F, Bahjat K, Bhardwaj N. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS ONE. 2010;5:e11144 pubmed publisher |
Stelekati E, Bahri R, D Orlando O, Orinska Z, Mittrücker H, Langenhaun R, et al. Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions. Immunity. 2009;31:665-76 pubmed publisher |
